Skip to content
value.today

Co-Diagnostics, Inc.

CODX
$4 Mmarket cap on Oct 30, 2026-90.0% since Jan 2024
Compare
World rank
#27,081
Revenue
$1 M
For year ending December-2025
Net income
$-47 M
-7564.5% margin
SEC filing
Employees
—

Co-Diagnostics, Inc. in brief

Co-Diagnostics, Inc. is a listed company in the Diagnostics and Research industry, based in Salt Lake City, Utah, USA. Its market value was $4 M on 30 October 2026, which makes it the 27,081st largest listed company in the world and the 4,427th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $47 M. Dwight H. Egan is its chief executive. Its largest product and service lines by sales in 2025 were Grant (33%). By market, the largest shares of its 2025 sales came from USA (93%). Its shares trade under the symbol CODX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc is a molecular diagnostics technology and innovation in disease detection and life sciences research through its enhanced detection of genetic material company. The headquarters is in USA.

Co-Diagnostics, Inc. timeline

3 events, 2016–2021
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 13 July 2017; shares registered for exchange trading on 11 July 2017.
  5. 2021
  6. 💰
    Record revenue of $98 million
    FY2021, the highest of the 8 years on record.

Events of Co-Diagnostics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$73 M$146 M$220 M$293 M2023202420252026

World rank over time

▼ down 9,791 places since 2022
2022-01-07: #17291#17,29120222022-12-25: #22864#22,86420222023-07-30: #26165#26,16520232024-01-05: #25709#25,70920242026-08-01: #22947#22,94720262026-10-13: #25366#25,36620262026-10-30: #27082#27,0822026

Rank in USA: #3,571 (Jan 2022) · #4,456 (Dec 2022) · #4,850 (Jul 2023) · #4,146 (Jan 2024) · #4,048 (Aug 2026) · #4,194 (Oct 2026) · #4,429 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
4.9×
Price / book
0.2×
Free cash flow yield
-710.5%
Net margin (TTM)
-5520.9%
Operating margin
-8091.9%
Return on equity
-230.2%
Liabilities / assets
16.6%
Net debt
$1M
Revenue growth
-84.2%
R&D / revenue
3087.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-6M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-6M$0MFY19Fiscal year ending Dec 2020: revenue $75M, net income $42M$75MFY20Fiscal year ending Dec 2021: revenue $98M, net income $37M$98MFY21Fiscal year ending Dec 2022: revenue $34M, net income $-14M$34MFY22Fiscal year ending Dec 2023: revenue $7M, net income $-35M$7MFY23Fiscal year ending Dec 2024: revenue $4M, net income $-38M$4MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-47M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M-84.2%$-50M$-47M-7564.5%
Dec 2024$4M-42.4%$-40M$-38M-960.2%
Dec 2023$7M-80.1%$-43M$-35M-518.8%
Dec 2022$34M-65.0%$-27M$-14M-41.6%
Dec 2021$98M+31.3%$46M$37M37.5%
Dec 2020$75M+35400.0%$42M$42M57.0%
Dec 2019$0M+425.0%$-6M$-6M-2952.4%
Dec 2018$0M—$-6M$-6M-15675.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-29M$1M$-30M$-35.25—
Dec 2024$-29M$1M$-30M$-37.22—
Dec 2023$-22M$1M$-23M$-1.20—
Dec 2022$7M$1M$5M$-0.45—
Dec 2021$41M$1M$40M$1.23—
Dec 2020$28M$1M$27M$1.52—
Dec 2019$-6M$0M$-6M$-0.37—
Dec 2018$-4M$0M$-4M$-0.50—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$1M
Net income, trailing 12 months
$-47M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-11M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-8M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-8M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-6M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-26M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-9M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-6M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-6M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+86.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Co-Diagnostics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-50 M
Net income
$-47 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$25 M
Total liabilities
$4 M
Total equity
$21 M

As of December-2025

Top 24 institutional investors in Co-Diagnostics, Inc.#

As of Sep 30, 2026
24 institutions held 290,662 shares (about 2.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 24 largest institutional investors in Co-Diagnostics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC58,2750 (0.00%)0.55%$0 MNov 13, 2026
2Geode Capital Management, LLC49,599+24,024 (+93.94%)0.47%$0 MNov 6, 2026
3Private Advisory Group LLC39,3870 (0.00%)0.37%$0 MNov 6, 2026
4HRT Financial LP30,355New0.29%$0 MNov 13, 2026
5Citigroup Inc25,301New0.24%$0 MNov 4, 2026
6Jane Street Group, LLC24,086-65,154 (-73.01%)0.23%$0 MNov 12, 2026
7Vanguard Fiduciary Trust Co19,7760 (0.00%)0.19%$0 MNov 13, 2026
8Susquehanna International Group, LLP15,986-15,253 (-48.83%)0.15%$0 MNov 16, 2026
9State Street Corp14,8000 (0.00%)0.14%$0 MNov 12, 2026
10Tower Research Capital LLC (TRC)7,684New0.07%$0 MNov 16, 2026
11Jpmorgan Chase & Co1,993+1,990 (+66333.33%)0.02%$0 MNov 12, 2026
12UBS Group AG1,477-14,614 (-90.82%)0.01%$0 MNov 10, 2026
13Morgan Stanley1,452-1,425 (-49.53%)0.01%$0 MNov 13, 2026
14SBI Securities Co., Ltd.140+59 (+72.84%)0.00%$0 MOct 22, 2026
15Smartleaf Asset Management LLC1330 (0.00%)0.00%$0 MNov 10, 2026
16Berthel, Fisher & Company Financial Services, Inc.100New0.00%$0 MNov 13, 2026
17Wells Fargo & Company/mn810 (0.00%)0.00%$0 MNov 16, 2026
18Osaic Holdings, Inc.100 (0.00%)0.00%$0 MNov 12, 2026
19BFC Planning, Inc.80 (0.00%)0.00%$0 MNov 13, 2026
20NewEdge Advisors, LLC60 (0.00%)0.00%$0 MNov 13, 2026
21Pinnacle Financial Group, Inc.6—0.00%$0 MNov 16, 2026
22FMR LLC4-3 (-42.86%)0.00%$0 MNov 10, 2026
23Harbour Investments, Inc.20 (0.00%)0.00%$0 MNov 9, 2026
24Northwestern Mutual Wealth Management Co10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Co-Diagnostics, Inc.#

2 funds hold shares worth $0 M (about 0.6% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Co-Diagnostics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.58,275$0 M0.55%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC39$0 M<0.01%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Co-Diagnostics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
12
since
Co-Diagnostics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Eugene DurenardDirectorGrant or award+1,695——10,668Form 4
filed Brian Lee BrownChief Financial OfficerGrant or award+3,750——23,729Form 4
filed Edward L. MurphyDirectorGrant or award+1,695——11,084Form 4
filed Dwight H. EganChief Executive Officer, DirectorGrant or award+4,584——29,526Form 4
filed Richard David AbbottPresidentGrant or award+1,890——4,097Form 4
filed James B. NelsonDirectorGrant or award+1,695——10,668Form 4
filed Richard S. SerbinDirectorGrant or award+1,695——10,751Form 4
filed Dwight H. EganChief Executive Officer, DirectorDisposal to the company-1,633$5.070$8 K27,893Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Co-Diagnostics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
981,329
46.8% of shares · 2.24 days to cover
Buybacks, Q4 2023
$0.2M
Q4 2023
Shares sold short, last 24 reportsAll stocks →
Co-Diagnostics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0.2M
Q3 2023Q3 2023$0.2M
Q2 2023Q2 2023$0.6M
Q1 2023Q1 2023$0.5M
Q4 2022Q4 2022$1.2M
Q3 2022Q3 2022$10.4M

Trading halts

  • 2026-07-01 18:25 UTC, code LUDP, resumed 18:30 UTC
  • 2026-07-01 13:56 UTC, code LUDP, resumed 14:01 UTC
  • 2026-07-01 13:40 UTC, code LUDP, resumed 13:50 UTC
  • 2026-06-02 13:35 UTC, code LUDP, resumed 13:45 UTC
  • 2026-05-27 14:54 UTC, code LUDP, resumed 15:04 UTC

Fails to deliver

  • : 32,988 shares at $0.40
  • : 3,204 shares at $0.44
  • : 207 shares at $0.55
  • : 16,865 shares at $0.64
  • : 1,506 shares at $0.72

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Co-Diagnostics, Inc. scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.2×Price to book 0.2× against Diagnostics and Research's median of 3.7×.
    • ✗Price to sales below its peers' median4.9×Price to sales 4.9× against Diagnostics and Research's median of 4.5×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 3
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-35.25 vs -37.22Diluted EPS -35.25 in fiscal 2025 against -37.22 the year before (report's currency).
    • ✗Net income higher than five years earlier-$47 M-$47 M in fiscal 2025 against $42 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$47 MNet income -$47 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-125.9%-125.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.87 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-10.11Z-score -10.11 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year31.6%Diluted shares up 31.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Co-Diagnostics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Co-Diagnostics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.63.96.83498750.20.00.0—
Cost of revenue0.21.04.25.5r12170.10.00.0—
Gross profit0.42.92.629r86580.10.00.0—
Research and development19212317153.21.41.41.00.7
Selling and marketing2.44.56.97.3134.71.11.20.40.1
General and administrative9.1161414128.33.53.63.10.8
Operating expenses5143455640166.06.14.61.7
Operating income−50−40−43−27r4642−5.9−6.1−4.6−1.7
Interest expense and finance costs——————0.1r0.10.30.2
Other non-operating income (expense)1.72.54.68.1r−0.40.9−0.3−0.2−2.4—
Income before tax−49−38−38−194643−6.2−6.3−7.0−1.9
Income tax−1.60.1−2.8−4.69.00.1————
Net income attributable to shareholders−47−38−35−143742−6.2−6.3−7.0−1.9
Earnings per share, basic-35.25-37.22r-1.20-0.451.271.59-0.37r-0.50-0.63—
Earnings per share, diluted-35.25-37.22r-1.20-0.451.231.52-0.37r-0.50-0.63—
Shares, weighted average (basic)1.31.0r2931292717———
Shares, weighted average (diluted)1.31.0r293130281712119.9
Balance sheet
Cash and cash equivalents122.9152389430.91.03.51.0
Short-term investments—2744581.34.3————
Receivables0.20.10.33.521120.10.0——
Inventory1.01.11.75.32.08.00.20.00.0—
Other current assets0.61.31.60.8r2.3—————
Current assets14326293r11568r1.61.14.51.2
Property, plant and equipment2.32.83.02.51.90.90.2r0.20.20.1
Right-of-use (leased) assets1.22.13.00.4——————
Goodwill————15—————
Other intangible assets7.226262727—————
Non-current assets——————0.60.50.20.1
Total assets2564r95123r160712.21.64.71.3
Accounts payable1.93.31.51.0r0.60.60.00.10.00.0
Customer deposits——————0.3—2.2—
Debt due within a year———————1.9—2.6
Current liabilities3.57.35.73.9r134.1r0.32.40.6r3.8
Long-term debt———————1.90.3—
Lease liabilities (non-current)0.61.22.20.1——————
Non-current liabilities0.62.43.64.7130.5r0.20.30.2r0.4
Total liabilities4.19.79.38.6r264.50.52.60.84.3
Retained earnings−80−33r4.640r5418−25−19−12−5.5
Shareholders' equity2154r86r115r134r671.7−1.13.9−3.0
Total liabilities and equity2564r95123r160712.21.64.71.3
Shares outstanding2.11.1r313134291713r129.9r
Cash-flow statement
Depreciation and amortization1.11.41.21.30.30.10.10.10.00.0
Share-based compensation2.25.48.37.55.52.71.11.32.00.1
Cash from operating activities−29−29−226.64128−5.5−4.1−3.2−1.3
Capital expenditure−0.7−0.7−1.4−1.4−0.7−0.8−0.1−0.0−0.1−0.0
Acquisitions, net of cash acquired————−1.2—————
Cash from investing activities261715−584.1−5.8−0.4−0.4−0.2−0.0
Debt issued———————2.0——
Shares issued———0.20.5195.50.07.1—
Shares bought back——−1.4−14——————
Cash from financing activities120.1−1.4−140.5205.91.95.92.3
Change in cash8.9−12−8.1−664642−0.1−2.62.51.0
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Co-Diagnostics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$0 M67%
  • Grant$0 M33%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Co-Diagnostics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$529 K
Dwight Egan
Other top executives, average
$391 K
the CEO earned 1.4× this
$100 invested is now
$13
Co-Diagnostics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dwight Egan$529 K$276 K$391 K$13
2024Dwight Egan$717 K$421 K$501 K$56

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Co-Diagnostics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 1 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 6 · Results announced 8

Co-Diagnostics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementNew debtUnregistered share sale8-K/A
Shareholder vote8-K
Material agreementNew debtUnregistered share sale8-K
Shareholder vote8-K
Shareholder vote8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Material agreementAgreement ended8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Co-Diagnostics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2021$47 MPrivate placement after listing$10 to $50 million22equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Co-Diagnostics, Inc. compares in Diagnostics and Research

  • Market cap$4 M · higher than 2% of 110
  • Revenue$1 M · higher than 5% of 123
  • Revenue growth-84.2% · higher than 1% of 89
  • Price / sales4.9× · lower than 43% of 85
  • Price / book0.2× · lowest of 84

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Co-Diagnostics, Inc.🇺🇸$4 M——-84.2%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Co-Diagnostics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Co-Diagnostics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Co-Diagnostics, Inc.? Suggest a correction